Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.
Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy.
复制标题
用于癌症治疗的白细胞衍生仿生纳米颗粒药物递送系统
DOI：
10.1016/j.apsb.2017.12.001
复制
发表时间：
2018-01
期刊：
影响因子：
--
通讯作者：
Chen J
中科院分区：
文献类型：
--
作者：
Huang Y;Gao X;Chen J
低系统毒性肿瘤的精确给药是药学研究人员最重要和最具挑战性的任务之一。尽管纳米治疗领域取得了进展，但人工合成纳米载体的使用仍然面临着一些挑战，包括从血液循环中快速清除和克服多种生理障碍的能力有限，这阻碍了纳米颗粒治疗的临床应用。由于白细胞（包括单核/巨噬细胞、中性粒细胞、树突状细胞和淋巴细胞）靶向肿瘤并能跨越生理屏障迁移，白细胞越来越多地被用作将纳米颗粒转移到肿瘤的载体。在这篇综述中，我们特别关注白细胞的分子和细胞机制，白细胞可以作为一种载体，将纳米颗粒输送到肿瘤中，并总结了如何利用白细胞来改善治疗终点的最新研究。我们还讨论了这种白细胞衍生的纳米颗粒给药系统的挑战和机遇。本文综述了白细胞来源的纳米颗粒递送载体的生物学特性和最近的临床前研究，特别关注细胞介导的方法，这些方法已经被开发出来，以克服药物递送的生理障碍。
Precise drug delivery to tumors with low system toxicity is one of the most important and challenging tasks for pharmaceutical researchers. Despite progress in the field of nanotherapeutics, the use of artificially synthesized nanocarriers still faces several challenges, including rapid clearance from blood circulation and limited capability of overcoming multiple physiological barriers, which hamper the clinical application of nanoparticle-based therapies. Since leukocytes (including monocytes/macrophages, neutrophils, dendritic cells and lymphocytes) target tumors and can migrate across physiological barriers, leukocytes are increasing utilized as carriers to transfer nanoparticles to tumors. In this review we specifically focus on the molecular and cellular mechanisms of leukocytes that can be exploited as a vehicle to deliver nanoparticles to tumors and summarize the latest research on how leukocytes can be harnessed to improve therapeutic end-points. We also discuss the challenges and opportunities of this leukocyte-derived nanoparticle drug delivery system. This review summarizes the biological features and recent preclinical investigations of leukocyte-derived nanoparticulate delivery vehicles with special focus on the cell-mediated approaches that have been developed to overcome the physiological barriers for drug delivery.
登录
查看更多内容
影响因子：
12.4
作者：
Dong X;Chu D;Wang Z
通讯作者：
Wang Z
影响因子：
11.5
作者：
Bol, Kalijn F.;Schreibelt, Gerty;Figdor, Carl G.
通讯作者：
Figdor, Carl G.
DOI：
10.1016/j.apsb.2016.01.007
发表时间：
2016-07
期刊：
Acta pharmaceutica Sinica. B
影响因子：
--
作者：
Hong EJ;Choi DG;Shim MS
通讯作者：
Shim MS
影响因子：
10.8
作者：
Choi, Mi-Ran;Stanton-Maxey, Katie J.;Clare, Susan E.
通讯作者：
Clare, Susan E.
DOI：
10.1038/nrc.2016.97
发表时间：
2016-08-23
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Fesnak AD;June CH;Levine BL
通讯作者：
Levine BL